Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Artificial Intelligence & Technology ETF (AIQ) vs Enveric Biosciences Inc (ENVB) Price & Performance

Global X Artificial Intelligence & Technology ETF
Enveric Biosciences Inc

Price performance

Price movement over the last 24 hours

Key statistics

Global X Artificial Intelligence & Technology ETF vs Enveric Biosciences Inc — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $61.96, while Enveric Biosciences Inc trades at $1.42 (market cap $5.84M). The key difference: Global X Artificial Intelligence & Technology ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.

AIQENVB
Sector
Sector/ThematicHealth
52-Week High
$70.14$17.40
52-Week Low
$43.28$1.28
Market Cap
$5.84M
Enterprise Value
$932.52K

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Artificial Intelligence & Technology ETF

AIQ trades at $63.84, up 3.22% with a neutral technical signal. The ETF shows strong momentum with moving averages indicating bullish sentiment while oscillators remain neutral. Recent performance highlights include turning $10,000 into $13,400 over six months, outperforming broader market indices. The fund has gained attention for its AI-focused strategy amid expanding market interest beyond mega-cap technology stocks.

The outlook remains positive as AI adoption accelerates, though valuations require monitoring. Key risks include thematic ETF concentration and fee structure considerations. Institutional interest in AI infrastructure spending supports long-term growth potential, but market volatility around AI stock rotations presents near-term challenges.

Enveric Biosciences Inc

ENVB trades at $1.48, up 2.07% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, with negative ROE and ROA, yet consistently beat earnings expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies.

The outlook is mixed: strong analyst support (75% buy ratings) and positive clinical updates contrast with deep losses and bearish technicals. Key risks include clinical trial outcomes and cash burn, while institutional financing provides near-term stability. Upside depends on successful drug development.

Returns comparison

Trailing returns across standard periods

About Global X Artificial Intelligence & Technology ETF

AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.

Read more on AIQ

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB